VRTX Vertex Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of VRTX Vertex Pharmaceuticals prior to the earnings report this week,
I would consider purchasing the 472.5usd strike price Puts with
an expiration date of 2024-11-8,
for a premium of approximately $14.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
VRTX
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated encouraging outcomes in clinical trials. This new drug represents a significant shift in pain management, offering an alternative to opioid medications.
Vertex is preparing to seek FDA approval for VX-548 within the year. If approved, this drug could substantially impact the healthcare industry and is projected to achieve peak annual revenues of 5 billion USD – approximately half of Vertex's current annual revenue.
Exploring investment opportunities, here is a technical analysis of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX):
On the Daily (D1) timeframe, the stock exhibits a 410.00 USD resistance level and support at 392.00 USD. The stock is currently trending downward. Notably, there have been three consecutive trading sessions with a gap up, suggesting that major players might be accumulating buy positions. If the downtrend persists, the next price target could be around 360.50 USD.
For traders, breaking the resistance at 410.00 USD could provide a buying opportunity, with a short-term target set at 421.00 USD. If the resistance is surpassed, holding a long position with a target of up to 436.50 USD might be considered for a medium-term strategy.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Stock of the Month: Vertex (VRTX)Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary:
Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading that emphasizes the importance of timing, risk management, and stock selection. Here’s a concise summary:
Trend Template: Minervini looks for stocks in a strong uptrend, using specific criteria for moving averages and price action to determine the health of the trend.
Volatility Contraction Pattern (VCP): He identifies stocks undergoing a VCP, a series of tightening price consolidations which often precede a significant breakout.
Risk Management: He sets strict stop-loss orders to limit potential losses, often using a maximum risk threshold per trade to manage overall portfolio risk.
Buy Points: Minervini waits for a proper pivot point before entering a trade, ensuring the stock is moving on high volume out of a sound base pattern.
Leadership: Preference is given to market leaders, stocks that outperform the market with strong earnings growth, sales, return on equity, and profit margins.
Market Direction: He trades in harmony with the overall market direction, increasing exposure during bull markets and preserving capital during bear markets.
By focusing on these key principles, Minervini aims to capture significant trends, minimize losses, and compound gains efficiently. Remember, this strategy requires discipline, continuous learning, and the ability to adapt to changing market conditions.
Stock of the Month November: Vertex
Detailed Technical Analysis
Price and Moving Averages : The price of VRTX has recently experienced a bullish breakout. It is trading above all key moving averages (MA), including the 50-day, 100-day, and 200-day MAs, which are aligned in ascending order—a bullish signal known as a 'golden cross'. The 50-day MA is often used as a short-term trend indicator, and its position above the longer-term MAs suggests a strong upward trend.
Volume : There's a noticeable increase in volume accompanying the price rise, which is a positive sign as it indicates strong buying interest.
Moving Average Convergence Divergence (MACD): The MACD line is above the signal line and above zero, which is bullish. The histogram is showing increasing momentum to the upside.
Relative Strength Index (RSI): The RSI is above 70, which typically indicates overbought conditions. However, in strong trends, the RSI can remain overbought for extended periods.
IBD Ratings: The IBD (Investor's Business Daily) ratings show a high relative strength rating of 93, suggesting that the stock is outperforming 93% of all other stocks in terms of price performance.
Bollinger Bands: The price has moved towards the upper Bollinger Band, which could signal that the stock is overextended in the short term.
Support and Resistance: The chart shows previous resistance around the $360 level, which appears to have been decisively breached and may now serve as support.
Candlestick Analysis: The recent candlesticks show strong bullish bodies, which confirms the buyers' control.
Price Targets: If you're using chart patterns for price targets, the recent breakout suggests a continuation of the uptrend.
Potential Risks: The overbought RSI readings could indicate a potential pullback or consolidation in the near term. Additionally, the elevated volume on up days should be monitored to ensure it doesn't start declining, which could signal a weakening trend.
Here is a link top our updated portfolio:
www.tradingview.com
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and was set to cross the $100 billion market-capitalization threshold for the first time.
The company’s experimental pain medicine VX-548 produced statistically significant, clinically meaningfully reductions in pain intensity in people with diabetic peripheral neuropathy, a type of nerve damage that can affect people with diabetes, Vertex said in a release.
The pain control seen with the drug appears comparable to the “gold standard” pain medicine pregabalin, which is marketed by Viatris Inc. under the brand name Lyrica, Evercore ISI analyst Liisa Bayko wrote in a report Wednesday. Evercore analysts raised their price target on Vertex shares to $405, from $389 previously.
The new data on the pain medicine “looks at least as good as or better than investor expectations,” Jefferies analysts said in a note Wednesday.
Vertex is working to quickly advance the treatment to Phase 3 studies in diabetic peripheral neuropathy, Vertex’s chief medical officer, Dr. Carmen Bozic, said in a statement. Phase 3 results from a trial of the drug in acute pain are expected in the first quarter of next year.
Vertex shares have gained 37% in the year to date, while the S&P 500 is up 21%.
NASDAQ:VRTX is trading above the 50, 100 & 200-day Moving Averages indicating the trend might continue.
VRTX Entry, Volume, Target, StopEntry: with price above 354.47
Volume: with volume greater than 2M
Target: 391 area
Stop: Depending on your risk tolerance; 342.3 gets you 3/1 Reward to Risk Ratio.
This swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not take this trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
Is Vertex Pharmaceuticals a $500 Stock?Vertex Pharmaceuticals ticker symbol VRTX is in a serious uptrend. If price break above the next resistance zone around $315 before the next earnings we could see a steep rise in price.
Vertex is the stock I will watching closely next week. I am going long at market prices above 283 stopout at redline 264
Happy trading.
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago.
For me its a very good chance and low price for VRTX.
strong up move with good volume crossing the negative trend
crossed EMA200 and MA200 on daily chart and also on weeky chart
still above EMA200 and MA200 on monthly chart
still in positive trend since 2008
good position in the market
good cashflow for the next years, even if products are failing
LFMD - WAVE C ENDING - BUY SOON OR OPTIONS LONGER TERMAll,
LFMD had game changing fundamentals last quarter but still under downtrend resisance #2. This is a 3/4 retracement wave C should be ending RSI tells the story on the daily. I am watching EXTREMELY closely here. I think this is going to pop worst case is a double bottom at 7.7 or near it in which case I will absolutely be all in. Fundamnentally/valuation wise I personallly see LFMD at 14-18$ range and probably will go into 20's again from demand/lower float than most in category.
As always watch the entire market first and do not enter too early. Just wait for the stars to align and for the break up to happen. Also remember almost everytime on breaks there is the first wave up but wave 2 is almost always a better and safer entry (depends how fast it moves)
KURA - UPDATE - ON LONG TERM SUPPORT CONFLUENCEAll,
I think previouis post I had my lines slightly off which of course makes a difference I think we are on confluence support and beyond oversold/downtrend has to at least pop somewhat in my opiniong even if its $4-5. Looking for a bounce soon between weekly/daily change then getting 5-10 OTM options for calls or could do it now with maybe Aug/Sept.